Hans Schambye, Galecto CEO
August 15, 2023 11:09 AM EDT
R&D

Galec­to ax­es lead can­di­date in lung dis­ease af­ter PhI­Ib miss, stock craters

Paul Schloesser

Associate Editor

Galec­to scrapped de­vel­op­ment of its lead can­di­date af­ter the drug missed the pri­ma­ry end­point in a mid-stage lung dis­ease tri­al and said it is eval­u­at­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times